Sesión plenaria - II congreso de la @FundacionTTCC . Proyecto REDESIGN: alt. moleculares al diagnóstico en SGC 🧬 implicaciones pronósticas 📈 y posibles 🎯 terapéuticas. Gracias al @ttccgroup y a los investigadores, en especial al Dr. @OlivaM_Onc . @OncoReporte @OncoAlert @_SEOM

🌍 Real-world meets real impact! Global multicenter study (n=666 | 11 countries) of Durva+GEM-CDDP in advanced BTC confirms TOPAZ-1:. 🎯 mOS 15.1m | mPFS 8.2m.🎯 ORR 32.7% | SD 45.2%.⚠️ AEs in 92.9% (≥G2: 46.6%). A global snapshot that echoes a pivotal.

👀 Ph2 MoST-CIRCUIT: Nivo+Ipi in advanced gynecological clear cell cancers (n=28 | 17 sites in Australia & New Zealand). 🎯ORR 54% (12% CR) | 6-mo PFS 58%.⚠️ G3-4 irAEs in 35% (incl. 1 myocarditis). All responses ongoing—no median DOR/OS reached. Small.

RT @OncoAlert: Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC)….

📢 ¡A must-read for residents!. A timely review in @FrontImmunol dives into antibody-based strategies for #HCC. 💉 ICIs (PD-1/L1, CTLA-4), bispecifics, ADCs.🎯 Explores mechanisms: immune modulation, angiogenesis inhibition, cytotoxicity.⚠️ Key.

RT @ICO_oncologia: L’@ICO_oncologia i l’@hbellvitge renoven l’acreditació europea per al tractament de càncers rars. Des de 2016 som centr….

RT @realbowtiedoc: #SuppOnc commentary from @CharlesJiangMD et al in @NatRevClinOncol . Despite ⬆️ pt willingness, #clinicaltrial enrollmen….

Honored to be listed among the most viewed oncologists at #ESMOGI25 💥 Proud to be part of a community pushing the boundaries of GI cancer through data and dialogue. In the end, it’s not just about being seen—it’s about helping others see more clearly 💡 . Thank you to @OncoAlert.

RT @Larvol: The Top Most Active Cancer Institutes that were leading the conversation during @myESMO Gastrointestinal (GI) Cancers Annual Co….

Almost forgot a favorite one! 💥 The phase III TALENTACE trial in intermediate/high burden HCC shows:. 🎯ORR 49% vs 34%.🎯mPFS 11.3 vs 7.0m.🎯mOS 34.5 vs 35.4m (immature). No new safety signals. Reinforces the LEAP-012 & EMERALD-1 momentum. A (T)ACE of talent indeed! ♠️

📢 ProvIDHe phase 3b study at #ESMOGI25: real-world Ivosidenib in pretreated mIDH1 CCA (n=262 pts | 15 countries). 🎯 mPFS 4.7m | mOS 15.5m.🎯 PR 5.7% | DCR 51.5% | mDoR 10.1m. Well-tolerated with no new safety signals — clarifying the ClarIDHy signal in global practice 🌍

💥 Phase II ShorTrip study #ESMOGI25:.SCRT → 1 cycle FOLFOX + 7 cycles FOLFOXIRI as TNT in #LARC. 🎯 pCR in 33% | MPR in 69%.🎯 77% completed all 8 cycles.⚠️ Toxicities manageable after early amendment. Short-course RT, long-term potential — the ShorTrip may lead to a major

🔬 STAR-01 at #ESMOGI25: tumor immune microenvironment (TIME) & survival in LARC after pre-op CRT . ▪️303 pts | 110 paired samples.🎯High post-CRT CD20+, TILs & low CD4/CD8 → improved EFS & OS ✅.🎯CD20+ cells ≥1% pre-CRT trended with better 5y-EFS (HR 0.59; p=0.051) ✅. TIME

💥 RATIONALE-306 at #ESMOGI25: Tislelizumab + chemo improves OS vs placebo + chemo in LA #ESCC. 🎯mOS: 25.6 vs 12.3m | HR 0.49.🎯mPFS: 9.7 vs 6.9m | HR 0.56.🎯ORR 61% vs 39% | DoR 22.1 vs 5.7m. For LA ESCC, tislelizumab adds reason to the rationale. 🔍.#OncoAlert @OncoAlert

🧵Dutch population-based cohort at #ESMOGI25 on definitive CRT for esophageal adenocarcinoma (n=872). 🎯mPFS 11.2 mo (95% CI: 8.8–13.4).🎯mOS: 18.9 mo | 1y: 66.5% | 3y: 24.9% | 5y: 13.5%.▪️OS worse with higher stage (HR stage I/II vs III: 1.53; vs IVa: 1.60; p<0.001). A dCRT

💥 IRIGA phase III trial at #ESMOGI25: mFOLFIRINOX vs mFOLFOX6 in 1L HER2− gastric/GEJ cancer:. 🎯 Higher ORR (31% vs 19%, p=0.014).🚫 No PFS (7.2 vs 6.8 mo, HR 0.81) or OS (13.4 vs 13.2 mo, HR 0.87) benefit.⚠️ ↑ Toxicity with mFOLFIRINOX (vomiting, nausea, mucositis)

💥 Phase II ABSK-011-201 #ESMOGI25.1L & 2L cohorts: Ipragratinib (FGFR4 inhibitor) + atezolizumab in FGF19+ #HCC. 🎯 ORR >50% across both groups.🎯 mPFS ≥7.0m | Durable responses.🧬 ~30% of HCC are FGF19+. If ~30% are FGF19+, maybe it’s not a needle — maybe it’s the haystack 🧑‍🌾

🚨 Who should undergo pancreatic cancer screening? 🤔 #ESMOGI25. ▪️PRSS1 (Hereditary Pancreatitis): RR ~53–87, risk up to 55%.▪️STK11 (Peutz-Jeghers): RR ~132, lifetime risk 11–36%.▪️CDKN2A (FAMMM): RR ~20–40, risk up to 25%.▪️SPINK1, TP53, BRCA1/2, PALB2, ATM, Lynch, FPC: All

💥 Proffered paper #ESMOGI25 - PARERE trial: ctDNA-guided sequencing in RAS/BRAF wt mCRC. 💉Panitumumab re-treatment (vs regorafenib) improved outcomes in hyperselected ctDNA-wt pt:. ⬆️ORR, DCR and PFS2 (3.9 vs 2.7 mo, p=0.03), but not PFS1 (4.1 vs 2.4 mo, p=0.12) .🛑 OS data

💥 Proffered paper #ESMOGI25 - Phase III ALTAIR: FTD/TPI as MRD-guided therapy in ctDNA+ CRC post-surgery . 🎯DFS: 9.3 vs 5.5 mo (P=0.107).⬆️ctDNA clearance with FTD/TPI (17.2% vs 12.4%).⚠️ G≥3 neutropenia in 56.6% | Dose skipping in 95.1% | Dose reductions in 37.7%. Yet,